Chat with us, powered by LiveChat
Lhasa Logo

Online

4th Annual Genotoxic Impurities Summit: Nitrosamines & Beyond 2024

We were delighted to be on the programme at the 4th Annual Genotoxic Impurities Summit. Lhasa Principal Scientist Michael Burns presented ‘Reactivities of N-nitrosamines against Common Reagents and Reaction Conditions’. Impurities may have a negative effect on the efficacy, safety, and quality of pharmaceutical components and products. The successful development and manufacturing of novel medications now […]

4th Annual Genotoxic Impurities Summit: Nitrosamines & Beyond 2024 Read More »

Classification of Potentially Mutagenic Impurities under the ICH M7 Guideline (in Japanese)

This webinar is specially prepared for the Japanese-speaking scientific community. Presentations will be delivered in English, with Japanese subtitles provided. It is designed for scientists, researchers, and regulatory professionals who want to strengthen their understanding of the ICH M7 guideline and its impact on the classification of mutagenic impurities. By attending, you will: Gain up-to-date

Classification of Potentially Mutagenic Impurities under the ICH M7 Guideline (in Japanese) Read More »

Ensuring API safety: Strategies for impurity and degradant management under ICH M7

Managing impurities in Active Pharmaceutical Ingredients (APIs) while meeting ICH M7 can be challenging. The need to quickly identify potential impurities, assess their toxicological risk and ensure compliance with mutagenicity and carcinogenicity guidelines demands a streamlined, reliable process. Held in Spanish, this webinar showcased how in silico tools Zeneth, Derek Nexus, and Sarah Nexus can

Ensuring API safety: Strategies for impurity and degradant management under ICH M7 Read More »

How to develop impurity control strategies without analytical testing

10 am (EST) / 3 pm (GMT) / 4pm (CET) This webinar detailed how to develop control strategies in line with ICH M7 guidelines without expensive and time-consuming analytical testing. We showed how you can assess carryover risk for potentially mutagenic impurities (including nitrosamines) in your drug development workflow. We were delighted to have Senior

How to develop impurity control strategies without analytical testing Read More »

ICH S1B(R1) industry and regulatory best practice for confident carcinogenicity assessment

The ICH S1B(R1) addendum is a globally recognised guideline that introduces a weight-of-evidence (WoE) approach to assessing the carcinogenic potential of pharmaceuticals.  It helps pharmaceutical organisations determine whether a two-year rat carcinogenicity study would provide additional insight into human safety. In this session, you will hear directly from former regulatory and industry experts who contributed

ICH S1B(R1) industry and regulatory best practice for confident carcinogenicity assessment Read More »

Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis

We were delighted to take part in an online seminar and panel discussion with ThermoFisher Scientific on 29th October. Nitrosamine Drug Substance related impurities (NDSRIs) remain a topic of significant concern to the pharmaceutical industry with multiple batch recalls in 2022+ across different drug classes including beta blockers and ACE inhibitors to name but a

Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis Read More »

Your forced degradation problem-solving session

We are looking forward to holding our upcoming webinar all about supporting forced degradation studies with in silico tools as part of your workflow. With Senior Scientist Jonathan Lockett, this session will cover four case studies demonstrating how in silico solution Zeneth can support confident interpretation of forced degradation studies and subsequently result in stress-free

Your forced degradation problem-solving session Read More »

Classification of potentially mutagenic impurities under the ICH M7 guideline

Watch our Lhasa webinar to deepen your understanding of the ICH M7 guidelines and their application in classifying mutagenic impurities.   Learn from regulatory and industry leaders through expert presentations and real-world case studies. The webinar agenda includes: Introduction to ICH M7 guidelines Dr Roland Froetschl, from the Federal Institute for Drugs and Medical Devices,

Classification of potentially mutagenic impurities under the ICH M7 guideline Read More »